Co-Authors
This is a "connection" page, showing publications co-authored by MICHAEL GILCREASE and STACY MOULDER.
Connection Strength
0.583
-
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.
Score: 0.164
-
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
Score: 0.149
-
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52.
Score: 0.130
-
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nat Commun. 2021 09 10; 12(1):5389.
Score: 0.051
-
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res. 2020 06 23; 22(1):69.
Score: 0.047
-
Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174.
Score: 0.043